Insulet Corp Stock Price, News & Analysis

Insulet Corporation (NASDAQ: PODD) announced FDA clearance for its Omnipod GO™, a tubeless insulin delivery device tailored for adults with type 2 diabetes, typically reliant on daily long-acting insulin injections. This innovative product offers a continuous insulin delivery for 72 hours and is available in seven programmed daily rates, enhancing convenience for users. Insulet aims to facilitate a smoother transition to insulin therapy and expects to launch the Omnipod GO in the U.S. in 2024. According to CEO Jim Hollingshead, the device is designed to change diabetes management perceptions and improve patient experiences.

Insulet Corporation (NASDAQ: PODD) plans to release its Q1 2023 financial results on May 4, 2023, after market closure. A conference call will follow at 4:30 p.m. Eastern Time for management to discuss the results. Investors can access this via the Investor Relations section of the website or by phone. Insulet is recognized for its innovative Omnipod® tubeless insulin pump technology, aimed at improving treatment for diabetes. The Omnipod 5 Automated Insulin Delivery System represents a significant advancement, offering seamless integration with continuous glucose monitors.

Insulet Corp. (PODD) will replace SVB Financial Group (SIVB) in the S&P 500 index, effective March 15, 2023. This change follows the Federal Deposit Insurance Corporation's (FDIC) action to place SVB Financial Group into receivership, rendering it ineligible for the index. Insulet's addition highlights its growing presence in the health care sector, while the deletion of SIVB reflects the significant challenges faced by financial institutions. The S&P Dow Jones Indices oversees these adjustments, which can impact the market perceptions and valuations of the involved companies.

Insulet Corporation (NASDAQ: PODD) reported its financial results for the year ended December 31, 2022, achieving full year revenue of $1.3 billion, up 18.8% from 2021. Total Omnipod revenue reached $1.2 billion, marking a 23.4% increase. However, Drug Delivery revenue declined by 34.2%. The company's gross margin fell to 61.7%, and operating income dropped significantly to $37.6 million from $126 million year-over-year. Adjusted net income was $91.1 million, compared to $59.2 million in the previous year. For 2023, Insulet anticipates revenue growth of 14% to 19% and plans a launch of the Omnipod 5.

Insulet Corporation (NASDAQ: PODD) presented new real-world evidence for its Omnipod 5 Automated Insulin Delivery System at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from February 22-25, 2023, in Berlin. The data showcased the device's effectiveness across various demographics, demonstrating strong glycemic control with minimal low glucose incidents. Omnipod 5, which has been available in the U.S. since August 2022, is set to launch in the UK mid-year and Germany later this year. Insulet plans to discuss future clinical trials and innovations at the symposium.